Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain

NCT00228605 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00228605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2005
Completion date
May 31, 2007
Enrollment
500
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic neuropathies, low back pain, migraine, osteoarthritis